MarketCapExport financials
Recro Pharma (REPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Recro Pharma Income Statement 2023-2011 | REPH
Brief overview of financial results at Recro Pharma
This overview is based on financial performance over the past five years. Recro Pharma reported revenue of $77.3 million in 2018 and $94.6 million by 2023. The five-year change reached +22.4%, while CAGR stood at 4.1%. Sales changed only slightly and remained broadly flat.
Gross profit changed from $34.2 million to $18.1 million (−46.9%). The cost base moved against the top-line trend and weighed on the gross result. Gross profit as a share of revenue changed from 44.2% to 19.2%. The contraction points to pressure from direct costs or weaker pricing power.
EBITDA was $20.3 million at the beginning and $4.6 million at the end of the period (−77.1%). The operating result developed less favorably than sales. EBITDA margin moved from 26.3% to 4.9%. A lower EBITDA share weakens the quality of the result.
The final result was −$79.7 million initially and −$13.3 million in the final year. The negative result improved without reaching break-even.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are a stronger final result. The main areas of concern are weaker operating efficiency, a low EBITDA margin and pressure from direct costs. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Recro Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
133 M | 81 M | - | - | - | - | - | - | - | - | - | - | - |
Shares |
95.2 M | 57.9 M | 44.1 M | 23.7 M | 22.4 M | 20.5 M | 19.1 M | 10.7 M | 8.49 M | 6.24 M | 156 K | - | - |
Historical Prices |
1.4 | 1.4 | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-13.3 M | -19.9 M | -11.4 M | -27.5 M | -18.6 M | -79.7 M | -50.1 M | -30.2 M | 3.03 M | -16.1 M | -1.96 M | -1.54 M | -2.87 M |
Revenue |
94.6 M | 90.2 M | 75.4 M | 66.5 M | 99.2 M | 77.3 M | 71.8 M | 69.3 M | 52 M | - | - | - | - |
Cost of Revenue |
76.5 M | 67.1 M | 55.5 M | 54.1 M | 51 M | 43.2 M | 38.2 M | 37.2 M | 28.1 M | - | - | - | - |
Gross Profit |
- | - | - | - | 48.2 M | 34.2 M | 33.6 M | 32.2 M | 23.9 M | - | - | - | - |
Operating Income |
-3.57 M | 279 K | 412 K | -8.34 M | 23.6 M | 12.5 M | -40.3 M | -25.8 M | -6.97 M | -11.9 M | - | - | - |
Interest Expense |
9.96 M | 14.2 M | 15.1 M | 19.2 M | 19 M | 8.11 M | 12 M | 5.59 M | 5.56 M | 4.27 M | 868 K | - | - |
EBITDA |
4.65 M | 7.69 M | 6.94 M | -2.38 M | 29.4 M | 20.3 M | -32.9 M | -18.2 M | -966 K | -11.9 M | 1.45 K | -794 K | -2.31 M |
Operating Expenses |
- | - | - | - | 22.5 M | 79.4 M | 61.1 M | 48.6 M | 27.2 M | 11.9 M | 1.09 M | - | - |
General and Administrative Expenses |
21 M | 22 M | 18.4 M | 18.1 M | 19.9 M | 36.9 M | 25.4 M | 12.7 M | 13 M | 4 M | 546 K | 339 K | 485 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Recro Pharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
101 M | 87.3 M | 84.8 M | 84.6 M | 56.7 M | 56.6 M | 56.4 M | 46.7 M | 51.4 M | 39 M | 29.7 M | 28.6 M | 23.6 M | 23.6 M | 23.4 M | 23.3 M | 22.5 M | 22.3 M | 21.9 M | 21.8 M | 20.7 M | 20.4 M | 19.2 M | 19.1 M | 19.1 M | 19.1 M | 19 M | 19 M | 10.8 M | 9.54 M | 9.25 M | 9.22 M | 9.12 M | 7.83 M | 7.77 M | 7.71 M | 7.71 M | 7.71 M | 1.75 M | 156 K | 156 K | 156 K | 156 K | - | - | - | - | - | - | - | - |
Net Income |
-4.59 M | -3.21 M | -4.68 M | - | -3.33 M | -3.12 M | -4.26 M | - | -3.49 M | 1.23 M | -6.76 M | - | -2.13 M | -6.01 M | -7.69 M | - | -4.3 M | -2.84 M | -1.98 M | - | -13.3 M | -12.7 M | -12.5 M | - | -9.06 M | -8.86 M | -8.09 M | - | -19.8 M | -14.4 M | -6.54 M | - | -2.15 M | -1.31 M | -4.14 M | - | -4.71 M | -2.79 M | -5.15 M | - | -504 K | -661 K | -409 K | - | - | - | - | - | - | - | - |
Revenue |
23.6 M | 21.8 M | 21.5 M | - | 21.6 M | 23.2 M | 21.2 M | - | 18.2 M | 18 M | 16.8 M | - | 19.3 M | 15.5 M | 21.8 M | - | 25.3 M | 31.3 M | 25.1 M | - | 18.3 M | 21.7 M | 19.5 M | - | 17.1 M | 16.9 M | 18.7 M | - | 17 M | 17.3 M | 17.7 M | - | 16.5 M | 18.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
19.9 M | 17.3 M | 19.3 M | - | 16.1 M | 17.5 M | 16.1 M | - | 13.2 M | 12.3 M | 14.3 M | - | 11.7 M | 11.6 M | 18.3 M | - | 11 M | 14.1 M | 14.4 M | - | 8.47 M | 12.1 M | 10.5 M | - | 6.88 M | 10.4 M | 10.5 M | - | 5.74 M | 9.55 M | 10.3 M | - | 10 M | 9.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.76 M | -968 K | -2.6 M | - | 215 K | 302 K | -851 K | - | 336 K | 1.84 M | -2.86 M | - | 2.48 M | -1.02 M | -2.57 M | - | 789 K | 2.35 M | 1.65 M | - | -13.6 M | -13.3 M | -12.8 M | - | -10.7 M | -9.43 M | -7.3 M | - | -3.92 M | -6.77 M | -5.02 M | - | -164 K | 373 K | -4.14 M | - | -4.72 M | -2.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
2.91 M | 2.31 M | 2.14 M | - | 3.54 M | 3.42 M | 3.41 M | - | 3.82 M | 3.96 M | 3.9 M | - | 4.61 M | 5 M | 5.15 M | - | 5.42 M | 5.37 M | 3.76 M | - | 2.2 M | 2.19 M | 2.1 M | - | 1.24 M | 1.21 M | 1.18 M | - | 1.45 M | 1.32 M | 1.51 M | - | 1.99 M | 1.69 M | 4.27 M | - | 4.27 M | 4.27 M | 4.27 M | - | 221 K | 213 K | 203 K | - | - | - | - | - | - | - | - |
EBITDA |
4.29 M | 2.97 M | -693 K | - | 5.73 M | 3.9 M | 941 K | - | 5.14 M | 4.88 M | -1.43 M | - | 4.06 M | 491 K | -1.07 M | - | 3.06 M | 4.59 M | 3.74 M | - | -11.6 M | -11.4 M | -11 M | - | -8.83 M | -7.56 M | -5.46 M | - | -2.68 M | -5.53 M | -3.75 M | - | 2.57 M | 1.64 M | -4.14 M | - | -4.72 M | -2.8 M | 9.69 K | - | 1.33 K | 969 | 485 | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.14 M | - | 4.72 M | 2.8 M | 874 K | - | 283 K | 449 K | 206 K | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.31 M | 5.27 M | 4.66 M | - | 5.08 M | 5.16 M | 5.71 M | - | 4.61 M | 3.79 M | 4.68 M | - | 4.42 M | 4.26 M | 5.45 M | - | 6.88 M | 10 M | 14.2 M | - | 6.97 M | 13 M | 9.52 M | - | 6.64 M | 6.32 M | 4.03 M | - | 3.84 M | 2.76 M | 2.66 M | - | 3.48 M | 2.6 M | 2.39 M | - | 1.08 M | 959 K | 647 K | - | 161 K | 204 K | 91.7 K | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Recro Pharma (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
Canada
China
Irlanda
Schweden
